Claims for Patent: 4,686,104

Summary for Patent: 4,686,104

Title:	Methods of treating bone disorders
Abstract:	Metal-containing compounds have been found to decrease calcium resorption from bone. These compounds, when administered to patients who are suffering from diseases characterized by accelerated bone resorption, impede the flow of bone calcium into the blood and increase the calcium content of bone tissue.
Inventor(s):	Bockman; Richard S. (New York, NY), Warrell, Jr.; Raymond P. (New York, NY)
Assignee:	Sloan-Kettering Institute for Cancer Research (New York, NY)
Application Number:	06/853,144
Patent Claims:	1. A method of decreasing bone resorption comprising administering to a subject with a bone resorptive disorder a pharmaceutically acceptable composition containing a germanium or platinum containing compound useful in decreasing bone resorption in an amount sufficient to cause bone resorption. 2. A method as in claim 1, wherein said disease is periodontal disease. 3. A method as in claim 1, wherein said disease is cancer related. 4. A method as in claim 1, wherein said disease is hypercalcemia. 5. A method as in claim 1, wherein said disease is osteoporosis. 6. A method as in claim 1, wherein said disease is caused by a parathyroid hormone, a cytokine, or other bone-resorbing factor lymphokine related compound. 7. A method as in claim 1, wherein said disease is malignant bone metastases. 8. A method as in claim 1, wherein said disease is Paget's disease. 9. A method as in claim 1, wherein said disease is an inflammatory disorder of bones or joints. 10. A method as in claim 1, wherein said subject is a human. 11. A method as in claim 1, wherein said subject is a veterinary subject. 12. A method as in claim 1, wherein said compound is administered intra-orally in a topical formulation comprising a concentrated rinse, gel, or other pharmaceutically acceptable carrier. 13. A method as in claim 1, wherein said compound is administered intravenously, subcutaneously, or intramuscularly. 14. A method as in claim 1, wherein said compound is administered by continuous intravenous infusion. 15. A method of claim 1, wherein said compound is administered by intravenous injection comprising an amount ranging from about 1-450 mg/sq m/day. 16. A method as in claim 1, wherein said compound is administered orally, topically, sublingually, per rectum or transdermally. 17. A method as in claim 1, wherein said compound is administered orally, topically, sublingually, per rectum or transdermally in an amount ranging from about 0.5-20 grams/day. 18. A method as in claim 1, wherein said compound is a platinum containing compound. 19. A method as in claim 1, wherein said compound is a germanium containing compound. 20. A method as in claim 18, wherein said compound is cis-diammine dichloro-platinum II. 21. A method as in claim 18, wherein said compound cis-diammine 1,1-cyclobutane dicarboxylate platinum II. 22. A method as in claim 19, wherein said compound is spirogermanium. 23. A method as in claim 20, wherein said compound is administered by intravenous, intramuscular, or subcutaneous injection. 24. A method as in claim 20, wherein said compound is administered in an amount ranging from about 1 to about 120 mg/sq m/day. 25. A method as in claim 21, wherein said compound is administered by intravenous, intramuscular, or subcutaneous injection. 26. A method as in claim 21, wherein said compound is administered in an amount ranging from about 1 to about 450 mg/sq m/day. 27. A method as in claim 21, wherein said compound is administered in an amount ranging from about 3 to about 100 mg/sq m/day. 28. A method as in claim 22, wherein said compound is administered by intravenous, intramuscular, or subcutaneous injection. 29. A method as in claim 22, wherein said compound is administered in an amount ranging from about 0.5 to about 100 mg/sq m/day. 30. A method as in claims 22 or 24, wherein said compound is administered orally, sublingually, rectally, or transdermally. 31. A method as in claim 22, wherein said compound is administered in an amount ranging from about 0.5 to about 20 grams/day.

Details for Patent 4,686,104

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2005-04-30